If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
174
results.
Updated on
29/08/2025 [06:52:00]
Absstract of: US2025270250A1
The disclosure is generally related to spherical nucleic acids (SNAs) comprising a protein corona, wherein the SNA comprises (i) a nanoparticle core and (ii) one or more oligonucleotides attached to the surface of the nanoparticle core, wherein the protein corona comprises a plurality of proteins. The disclosure also provides methods of using the same. The disclosure further provides methods of improving stability and/or extending blood circulation half-life of a spherical nucleic acid (SNA), the SNA comprising a nanoparticle core and one or more oligonucleotides attached to the surface of the nanoparticle core, the method comprising adsorbing a plurality of proteins on the surface of the SNA.
Absstract of: AU2024208905A1
A mixture for treating a tumor, which includes an agent which turns into a hydrogel by addition of calcium ions, a vehicle carrying the agent in a manner allowing injection of the mixture into a tumor; and radium radionuclides bonded to the agent in a concentration sufficient to treat the tumor by radiotherapy.
Absstract of: AU2024211148A1
Provided herein is a method of making circular RNA, a method of isolating circular RNA and compositions comprising circular RNA.
Absstract of: AU2024213893A1
Nanoparticles suitable for delivery of a linear DNA molecule are provided. Nanoparticles suitable for delivery of mRNA or DNA are provided. Further provided are uses of the nanoparticles including the use of the nanoparticles for treating disease and the use of the nanoparticles in vaccines.
Absstract of: AU2023380329A1
Aspects disclosed herein include a material and formulations having the material, the material comprising functionalized artificial melanin nanoparticles, wherein: each functionalized artificial melanin nanoparticle comprises a surface functionalized with a modifier agent via a linker group; wherein the modifier agent comprises the linker group and a functional group attached to the linker group; and wherein the linker group is an amine group. Aspects also include a method of healing skin damage using the disclosed formulations.
Absstract of: WO2024086810A1
The present disclosure relates to lymphatic endothelial cell (LEC)-specific lipid nanoparticle comprising a sterol, an ionizable lipid, a PEGylated lipid, and a phospholipid. Also disclosed herein are compositions comprising the LEC-specific lipid nanoparticle and a therapeutic agent. The present disclosure further relates to methods of delivering an agent to a lymphatic system in a subject, comprising administering to the subject an effective amount of the composition of the LEC-specific lipid nanoparticle and therapeutic agent.
Absstract of: WO2024085837A1
The invention relates to the biocompatible complex formed by binding a pyrene- methanol-bonded therapeutic peptide (Cycas Revoluta anticancer peptide 1, Cr-ACP1) to the quadrilateral graphene nanohole surface with a defective structure, and the synthesis method of this complex. With the therapeutic peptide attached to the biocompatible complex, treatment is provided to healthy tissues with minimal side effects, and the transport of said complex to the cancer cell occurs in a controlled manner.
Absstract of: CN120035760A
Methods and systems for analyzing lipid nanoparticles using size exclusion chromatography in combination with multi-angle light scattering are disclosed.
Absstract of: CN120225659A
The present disclosure provides methods for producing and/or purifying secretory groups, extracellular vesicles, and fractions thereof from progenitor cells; also provided are compositions containing such secretion-producing groups, extracellular vesicles, and fractions thereof. The present disclosure also provides methods of analyzing the activity, function, and potency of these secretory groups, extracellular vesicles, and fractions thereof. The present disclosure also relates to therapeutic uses of secretograms, extracellular vesicles and fractions thereof. The present disclosure also relates to scalable culture regimens that comply with good production specifications (GMP) for issuing clinically available secretory groups.
Absstract of: US2025242049A1
It is an object of the present invention to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem/progenitor cell or mesenchymal stem cells, and a method of delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule, wherein the lipid nanoparticle comprises an ionizable lipid, and the targeting molecule specifically binds to a marker of hematopoietic stem/progenitor cells or mesenchymal stem cells.
Absstract of: WO2024084007A1
The present invention relates to inhibitors, pharmaceutical compositions and methods for inhibiting the expression of Fos-related antigen-1 (Fra-1) or Fos-related antigen-2 (Fra-2) in fibrogenic tissue cells for use in the treatment or prevention of organ or tissue fibrosis. The inhibitor of the present invention is characterized in that it interferes with Fra-1 or Fra-2 expression, resulting in a reduction in the amount of Fra-1 or Fra-2 in said fibrogenic cells to levels found in non-fibrotic healthy cells or tissues.
Absstract of: CN120092089A
The present invention relates generally to compositions and methods for inhibiting coronavirus replication and treating diseases caused by coronavirus infection. More specifically, the present invention provides nucleic acids capable of inhibiting replication of coronavirus (e.g., SARS-CoV-2) and their use in treating viral infected patients.
Absstract of: EP4606370A1
According to one embodiment of the present disclosure, a method for fusing lipid nanoparticles is provided. In some embodiments, the method is a method including: causing a fibrous structure to capture a first lipid nanoparticle; causing the fibrous structure to capture a second lipid nanoparticle; and causing the fibrous structure to contract.
Absstract of: EP4606388A1
The disclosure relates to the technical field of biological medicines, and particularly provides a metal-chelated polyphenol complex nanoparticle, a drug-lipid particle, preparation methods for the same, and the uses thereof. The present disclosure provides a metal-chelated polyphenol complex as a carrier for drugs for stability, delivery and the like, so that it interacts with other carriers to form a metal-chelated polyphenol complex nanoparticle for effective administration of negatively charged drug. High-efficiency systemic drug delivery can be achieved, while toxicity is significantly reduced compared to LNP containing cationic or ionizable lipids, enabling safe and effective treatment of diseases or disorders.
Absstract of: WO2024125823A1
The invention relates to new Lipid nanoparticles (LNPs) which can be used for nucleic acid delivery, wherein said LNPs comprise a nucleic acid and a nonionic or cationic cyclodextrin compound. The invention also relates to a process for making the same, and to the use thereof in the pharmaceutical field.
Absstract of: WO2024084089A1
Methods, systems, and uses for providing a lipid nanoparticle composition with advantageous nanoparticle properties are provided.
Absstract of: WO2024082067A1
Described herein is a fusion polypeptide comprising a sarbecovirus binding moiety linked to a nanocage monomer or subunit thereof, wherein the sarbecovirus binding moiety is capable of binding to SARS-CoV-2 and at least one sarbecovirus other than SARS-CoV-2. Also described are methods for treating and/or preventing sarbecovirus infection and/or a sarbecovirus-associated condition.
Absstract of: CN120535438A
本发明提供了一种两性离子脂质及其组合物和应用，属于生物医药技术领域。该两性离子脂质具有如下式（I）所示结构：#imgabs0#，（I）；R1和R2各自独立地选自单键、或者取代或未取代的C1~C20饱和或不饱和烷基；R1的n1个或R2的n2个亚甲基各自独立地被‑O‑、‑C(O)‑、‑C(O)O‑或‑C(O)NH‑所置换；且取代或未取代的C1~C20饱和或不饱和烷基上有取代基时，取代基选自羟基、巯基、C1~C20烷基中的一种或多种的组合。本发明两性离子脂质可以提升脂质纳米颗递送系统的转染率，提高核酸递送效率。
Absstract of: CN120531687A
本发明公开了一种基于金属有机框架的卡巴拉汀纳米粒及其制备方法，属于纳米药物技术领域。本发明金属有机框架为ZIF‑8，将卡巴拉汀封装负载于ZIF‑8孔隙内形成核‑壳结构，同时在ZIF‑8表面负载乳铁蛋白LF，形成LF‑Riv@ZIF‑8纳米粒。本发明利用ZIF‑8材料的高孔隙结构对卡巴拉汀进行封装负载，制备一种卡巴拉汀抗阿尔兹海默纳米粒，改善由于卡巴拉汀低水溶性、生物利用度低，胃肠道副反应较多及光热敏感性的特点导致的应用局限性。
Absstract of: CN120531703A
本发明提供预制载体在制备用于免疫细胞和干细胞的体外基因递送的产品中的应用，属于生物医药技术领域。本发明的预制载体在制备用于免疫细胞和干细胞的体外基因递送的产品中的应用，包括将预制载体与核酸在溶剂中混合，得到基于预制载体的组合物的步骤；所述预制载体组成包括：可电离脂质、磷脂、胆固醇以及聚乙二醇缀合脂质。本发明所述预制载体，可用于细胞及基因治疗的载体工具。
Absstract of: CN120531700A
本发明公开了一种靶向肺炎的仿生纳米系统及其制备方法和应用。所述靶向肺炎的仿生纳米系统包括包载抗菌药物的纳米颗粒，和包覆于所述纳米颗粒表面的NK细胞膜。本发明首次基于NK细胞膜实现仿生纳米系统靶向到细菌的定植部位，躲避巨噬细胞的吞噬以及穿透细菌形成的黏液层，开发针对肺炎抗菌药物的递送系统，为抗菌药物的递送提供了新思路、新方法。
Absstract of: CN120531704A
本发明涉及生物技术领域，特别涉及一种仿生纳米调节剂的制备方法及应用。本发明提供了仿生纳米调节剂，所述纳米调节剂包括治疗药物；所述治疗药物包括：Ce6和SB525334。将细菌外膜囊泡与包封Ce6和SB525334药物的PLGA通过挤压得到仿生纳米调节剂。在光动力治疗下，仿生纳米调节剂可以被中性粒细胞识别、摄取并递送至肿瘤组织。仿生纳米调节剂可以调控中性粒细胞向抗肿瘤N1型极化，并促进中性粒细胞释放中性粒细胞弹性蛋白酶，特异性杀伤肿瘤细胞，逆转肿瘤免疫抑制微环境。仿生纳米调节剂在光动力‑免疫疗法的联合治疗下，显著抑制肿瘤生长，增强了机体抗肿瘤免疫应答。
Absstract of: CN120531701A
本发明属于干眼症治疗领域，涉及一种用于治疗干眼症的白藜芦醇纳米制剂及其制备方法。白藜芦醇纳米制剂包括白藜芦醇，以及丝胶蛋白与甘草酸通过互穿作用形成的复合载体，所述复合载体包封所述白藜芦醇。本发明通过采用丝胶蛋白与甘草酸互穿形成的复合载体对白藜芦醇进行包封，有效地解决了传统白藜芦醇在治疗干眼症过程中因生物利用度低而导致的疗效不佳问题。该复合载体能够包封白藜芦醇，形成稳定的纳米丝状结构，该纳米丝状结构具有小于10nm的水动力直径，极大地提升了白藜芦醇的口服生物利用度以及在眼部组织的分布能力，进而显著提升白藜芦醇口服治疗干眼的药效。
Absstract of: CN120531702A
本发明提供预制载体在制备用于免疫细胞和干细胞的体外基因递送的产品中的应用，属于生物医药技术领域。本发明的预制载体在制备用于免疫细胞和干细胞的体外基因递送的产品中的应用，包括将预制载体与核酸在溶剂中混合，得到基于预制载体的组合物的步骤；所述预制载体组成包括：可电离脂质、磷脂、胆固醇以及聚乙二醇缀合脂质。本发明所述预制载体，可用于细胞及基因治疗的载体工具。
Nº publicación: CN120535540A 26/08/2025
Applicant:
苏州大学
Absstract of: CN120535540A
本发明公开了一种BODIPY衍生物和纳米制剂、相应的制备方法与用途，所述BODIPY衍生物以氟硼二吡咯为母核，通过调整取代基、扩展共轭体系制得。本发明的BODIPY衍生物和纳米制剂，其发射波长能够延伸至NIR‑II区，可以用来制备抑制肿瘤细胞生长的药物或近红外二区荧光成像剂。
BOPI
Electronic site
